www.chestpubs.org association. Further, nearly all published studies uniformly recommend that the inclusion of atelectasis as a cause of postoperative fever be discarded as historical conjecture and unsupported dogma. Mavros and colleagues 1 conclude that there is a need for additional large studies to precisely evaluate whether there is an association that the prior studies have not detected. We respectfully disagree, given the fi ndings of our most recent study. From our perspective, based on our large cohort of patients and the outcome of our study, rather than performing additional studies, it would seem more prudent and appropriate to simply discard old dogma. 
Response

To the Editor:
We thank Drs Kane and Backer for their correspondence on our recent article, which contributed to the discussion of the potential association between postoperative fever and atelectasis. 1 The authors conducted a retrospective cohort study, examining the potential association between postoperative fever and atelectasis in pediatric patients. 2 They concluded that no such association existed, and, thus, postoperative fever should not be attributed to atelectasis.
To our knowledge, a total of three studies, including the one by Drs Kane and Backer, 2 have specifi cally examined this association. In their correspondence, Drs Kane and Backer suggested that no further studies are necessary to confi rm the lack of association between atelectasis and postoperative fever and that this old idea should simply be discarded. Unfortunately, it is not so rare in clinical practice for clinicians to choose to follow their own rationale rather than what is suggested by the published evidence; in fact, several such cases have been published so far. 3 , 4 Regarding the potential association of atelectasis and postoperative fever , however, all the published studies have certain limitations, including methodologic concerns and a relatively small sample size. This fact does not allow, at least in our point of view, for fi rm conclusions to be drawn. Although the rather limited evidence implies no association between atelectasis and postoperative fever, we believe that future well-designed and wellconducted studies will be useful in reaching a safe conclusion, and convincing even the most doubtful minds.
Michael N. Mavros 
Montelukast for Bronchiolitis Obliterans Syndrome After Lung Transplantation
To the Editor: Correspondence Although their review is thorough, we have missed one important translational development, namely, the leukotriene B4 pathway in the pathophysiology of bronchiolitis obliterans syndrome after lung transplantation. Leukotriene B4 is a lipid mediator that has been shown to have potent chemotactic activity for effector T lymphocytes mediated through its receptor, BLT1. 2 In a murine model, Medoff and colleagues 2 have demonstrated that BLT1 controls effector CD8 1 T-cell traffi cking into the lung and that BLT1-mediated CD8 1 T-cell recruitment plays an important role in the development of airway fi broproliferation and obliteration. Indeed, in human lung transplant recipients, BLT1 is upregulated on T lymphocytes isolated from the airways of patients with bronchiolitis obliterans. 2 Montelukast, a drug used for the treatment of asthma, inhibits leukotriene activity. 3 In a pilot study of 11 patients with bronchiolitis obliterans syndrome after lung transplantation, the addition of montelukast to immunosuppressive drugs decreased FEV 1 decline after 6 months of treatment compared with a retrospective cohort of 11 patients. 4 Intervening in the leukotriene B4 pathway through the addition of montelukast may thus be another promising research direction with clinically relevant treatment implications for bronchiolitis obliterans syndrome after lung transplantation.
